T-cell prolymphocytic leukemia is a rare malignancy of post-thymic T-cells. It is characterized by lymphocytosis and splenomegaly.
It usually occurs in adults over 30 years and appears to be more common in males. No concrete risk factors have been identified apart from individuals with Ataxia telangiectasia being at increased risk. It is an aggressive malignancy and is chemotherapy resistant with median survival being about 7 months. The only potential curative treatment is Hematopoietic stem cell transplant.
By choosing to continue, you are confirming that you are a healthcare professional